The Chain Consists Of Two Or More Carbons Which Are Unsubtituted Or Have Acyclic Hydrocarbyl Substituents Only Patents (Class 514/654)
-
Publication number: 20090023791Abstract: NMDA receptor blockers, including pH-sensitive NMDA receptor blockers, are provided as neurprotective drugs that are useful in stroke, traumatic brain injury, epilepsy, and other neurologic events that involve acidification of brain or spinal cord tissue. Compositions and methods of this invention are used for treating neurodegeneration resulting from NMDA receptor activation. The compounds described herein have enhanced activity in brain tissue having lower than normal pH due to pathological conditions such as hypoxia resulting from stroke, traumatic brain injury, global ischemia that may occur during cardiac surgery, hypoxia that may occur following cessation of breathing, pre-eclampsia, spinal cord trauma, epilepsy, chrounic pain, vascular dementia and glioma rumors.Type: ApplicationFiled: May 8, 2008Publication date: January 22, 2009Applicant: Emory UniversityInventors: Stephen F. Traynelis, Dennis C. Liotta, James P. Snyder, Yesim Altas, David D. Mott, James J. Doherty, JR., Raymond J. Dingledine
-
Publication number: 20090018135Abstract: The present invention relates to methods for treating or preventing bowel disorders using calcimimetics.Type: ApplicationFiled: March 31, 2008Publication date: January 15, 2009Applicants: Amgen Inc., John Peter GEIBEL, Steven Charles HEBERTInventors: John Peter Geibel, Steven Charles Hebert, Patricia Hebert, David Martin, Deborah A. Russell
-
Publication number: 20090012182Abstract: Provided are crystalline forms of O-desmethylvenlafaxine succinate, methods for their preparation, and pharmaceutical composition thereof.Type: ApplicationFiled: June 16, 2008Publication date: January 8, 2009Inventors: Alexandr Jegorov, Eli Lancry, Anna Balanov
-
Publication number: 20090004279Abstract: A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the nebulized lidocaine or a lidocaine-like compound improves airway tolerance and deposition of the agent in the lungs and makes such deposition more safe, efficacious, controllable and predictable. The method of the invention is especially useful for enhancement of deposition of immunosuppressive agents in the lung(s) of transplant patients, improved tolerance of the drugs by reducing cough, and improving pulmonary drug deposition.Type: ApplicationFiled: September 10, 2008Publication date: January 1, 2009Inventors: Thomas Hofmann, Alan Bruce Montgomery, Kevin Stapleton, William R. Baker
-
Publication number: 20090005441Abstract: Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.Type: ApplicationFiled: June 25, 2008Publication date: January 1, 2009Applicant: Krele Pharmaceuticals, Inc.Inventor: Seth LEDERMAN
-
Publication number: 20090005458Abstract: The use of tapentadol for treating pain due to osteoarthritis.Type: ApplicationFiled: April 21, 2008Publication date: January 1, 2009Applicant: Gruenenthal GmbHInventors: Ferdinand Rombout, Claudia LANGE
-
Publication number: 20080312163Abstract: This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.Type: ApplicationFiled: June 13, 2007Publication date: December 18, 2008Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson, Craig Peterson
-
Publication number: 20080293751Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.Type: ApplicationFiled: November 15, 2007Publication date: November 27, 2008Inventors: Robert Greenhouse, Ralph New Harris, III, Saul Jaime-Figueroa, James M. Kress, David Bruce Repke, Russell Stephen Stabler
-
Publication number: 20080293735Abstract: The present invention is directed to a method for treating a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, comprising the step of increasing the ratio of dopaminergic neuronal to noradrenergic neuronal activity within the central nervous system and particularly the hypothalamus of the central nervous system of the patient.Type: ApplicationFiled: May 28, 2008Publication date: November 27, 2008Inventor: Anthony H. Cincotta
-
Patent number: 7456222Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.Type: GrantFiled: July 1, 2005Date of Patent: November 25, 2008Assignees: Sequella, Inc., The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Marina Nikolaevna Protopopova, Richard Edward Lee, Richard Allan Slayden, Clifton E. Barry, III, Elena Bogatcheva, Leo Einck
-
Publication number: 20080262086Abstract: Disclosed herein are substituted anthranilic acids, pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of such compounds for the treatment and/or management of hypertension, edema associated with congestive heart failure, hepatic disease, renal disease including nephrotic syndrome, or clearance of toxic substances from the body.Type: ApplicationFiled: April 18, 2008Publication date: October 23, 2008Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20080242718Abstract: The invention concerns in-vitro evaluation of intracellular biomarkers by doing blood testing. Concentrations of neurotransmitters in the platelet cells are utilized to identify chemical imbalance in the central nervous system. In one embodiment of the invention, testing data is analyzed by proprietary software algorithms by physicians and related health care professionals to diagnose and treat sufferers of chemical imbalance objectively. In another embodiment of the invention the testing and software predetermines risks of developing various neuropsychiatric conditions, like depression, Parkinson's, Alzheimer's, bipolar disorder, ADD/ADHD, autism, asperger's syndrome, OCD and other anxiety disorders, muscle disorders, etc.Type: ApplicationFiled: March 14, 2008Publication date: October 2, 2008Inventor: Sanjay Jasuja
-
Publication number: 20080206334Abstract: The present invention is directed to a controlled-release pharmaceutical composition providing a sustained delivery of the basic drug Terbutaline sulfate, said composition comprising at least Terbutaline sulfate or a derivative thereof as an active agent, and further comprising an inactive matrix, said matrix comprising a hydrophilic polysaccharide polymer mixture, said mixture comprising chitosan or a derivative thereof, and further comprising xanthan gum or a derivative thereof, wherein the ratio of xanthan gum and chitosan within said mixture is in the range from about 1:10 to about 10:1, and said composition optionally comprising sodium bicarbonate.Type: ApplicationFiled: December 29, 2005Publication date: August 28, 2008Inventors: Mayyas Al-Remawi, Adnan Badwan
-
Publication number: 20080187573Abstract: A fast dispersing solid pharmaceutical composition having a monoamine oxidase B inhibitor as the only active ingredient is disclosed for the treatment of Parkinson's disease. The composition is formulated to promote absorption through the buccal, sublingual, pharyngeal and/or esophageal mucous membranes, such that at least 5% of the active ingredient is absorbed in one minute, as determined by a buccal absorption test.Type: ApplicationFiled: September 5, 2007Publication date: August 7, 2008Inventors: Francesca Mary Brewer, Edward Stuart Johnson, Anthony Clarke
-
Publication number: 20080181959Abstract: The invention encompasses solid composites of the calcium receptor-active compounds, processes for preparing the solid composites, immediate and controlled-release pharmaceutical formulations comprising the solid composites, and methods of treatment therewith.Type: ApplicationFiled: August 30, 2007Publication date: July 31, 2008Inventors: Ilan Zalit, Uri Zadok
-
Publication number: 20080153808Abstract: Disclosed herein is a pharmaceutical composition comprising a serotonin-norepinephrine reuptake inhibitor and a pan-alpha-2 receptor agonist. The composition is effective for treating chronic pain, and methods of treating pain using the composition and compounds comprising it are also disclosed.Type: ApplicationFiled: December 12, 2007Publication date: June 26, 2008Applicant: Allergan, Inc.Inventors: Daniel W. Gil, John E. Donello
-
Publication number: 20080152640Abstract: The present invention relates to the use of at least one inhibitor of at least one ABC-transporter capable of transporting hyaluronan across a lipid bilayer, such as verapamil or valspodar, for the preparation of a pharmaceutical composition for the treatment of a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, e.g. arthritis. Furthermore, the present invention relates to a method for screening a compound which is suitable for the treatment of a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, e.g. arthritis. The present invention also relates to a method for screening a compound which reduces the transport of hyaluronan mediated by (an) ABC-transporter(s). Furthermore, the present invention relates to a method for identifying a subject at risk for a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, e.g.Type: ApplicationFiled: July 29, 2004Publication date: June 26, 2008Inventor: Peter Prehm
-
Publication number: 20080132442Abstract: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include greater than 30% by weight of the active agent, and may be formulated as solutions, solids, semisolids, microparticles, or crystals. Methods related to the implantation and use of the biodegradable drug delivery systems for treating nail unit conditions are also described.Type: ApplicationFiled: February 11, 2008Publication date: June 5, 2008Inventors: Frank M. Kochinke, Corinne Bright
-
Publication number: 20080124285Abstract: Described are merocyanine derivatives of formula (1a) or (1b) wherein n and o are integers from 2 to 4 and aminocyclohexenone intermediates. They are used in protecting human and animal hair and skin from UV radiation.Type: ApplicationFiled: December 8, 2004Publication date: May 29, 2008Inventors: Barbara Wagner, Thomas Ehlis, Stefan Muller
-
Publication number: 20080124398Abstract: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.Type: ApplicationFiled: February 6, 2008Publication date: May 29, 2008Inventors: GOPI VENKATESH, James M. Clevenger
-
Publication number: 20080124399Abstract: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration-time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.Type: ApplicationFiled: February 6, 2008Publication date: May 29, 2008Inventors: GOPI VENKATESH, James M. Clevenger
-
Publication number: 20080125360Abstract: The present invention relates to PYY or functional equivalents thereof for use in pharmaceutical compositions. The pharmaceutical compositions are in particular useful in the treatment of functional gastrointestinal disorders, such as irritable bowel disease and functional dyspepsia. The invention further relates to methods of treatment using said compositions. Further included is the combination of PYY or functional equivalents thereof with a secondary active ingredient such as an anti-emetic drug.Type: ApplicationFiled: May 18, 2005Publication date: May 29, 2008Inventor: Henrik Nilsson
-
Publication number: 20080118570Abstract: Included are compositions, and methods of making, coated controlled-release drug and ion exchange resin form complexes. Methacrylate coatings, which can be free of plasticizers particularly with Eudragit® NE type polymer, are preferred to enhance the control of drug release from the drug-resin complexes. Liquid formulations including the coated resin forms and a chelating agent to inhibit degradation are also included.Type: ApplicationFiled: November 20, 2006Publication date: May 22, 2008Inventors: Zhi Liu, Bei Chen, Danchen Gao, Mukti S. Rao, Arunya Usayapant
-
Publication number: 20080096973Abstract: A series of Z-stilbenes derivatives are disclosed, which have the structure as shown by formula 1. In the structure of formula 1, X is hydrogen, NHR, or nitro group, and R is hydrogen. Y and Z is independently hydrogen, halogen, C1-C10 alkyl, or C1-C10 alkoxyl. Furthermore, A is hydrogen, hydroxyl, or amino group. The compounds of the present invention have both aqueous solubility and anti-tumor activity. The Z-stilbenes derivatives of the present invention can further include a pharmaceutical carrier to form pharmaceutical compositions as potent anti-mitotic agents and anti-cancer agents.Type: ApplicationFiled: January 19, 2007Publication date: April 24, 2008Applicants: Taipei Medical University, National Health Research InstitutesInventors: Jing-Ping Liou, Jang-Yang Chang
-
Patent number: 7355079Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.Type: GrantFiled: April 5, 2005Date of Patent: April 8, 2008Assignees: The Regents of the University of California, Oregon Health & Science UniversityInventors: Thomas S. Scanlan, Matthew E. Hart, David K. Grandy, James R. Bunzow, Motonori Miyakawa, Edwin Saavedra Tan, Katherine L. Suchland
-
Patent number: 7339079Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.Type: GrantFiled: June 17, 2005Date of Patent: March 4, 2008Assignees: The Regents of the University of California, Oregon Health & Science UniversityInventors: Thomas S. Scanlan, Matthew E. Hart, David K. Grandy, James R. Bunzow
-
Publication number: 20080039443Abstract: Provided herein methods of screening for potential antidepressant compounds effective to increase production of cellular CDP-diacylglycerol and synthesis of inositol phospholipid in depression-related areas of the brain. Also, provided are methods of diagnosing and treating depressive or mood disorders in a subject by administering these screened antidepressant compounds. Further provided is a method of determining the therapeutic efficacy of an antidepressant drug regimen by comparing the ratio of CDP-diacylglycerol/inositol phosphate after treatment to a basal ratio in a subject.Type: ApplicationFiled: August 9, 2007Publication date: February 14, 2008Inventors: Kimberly R. Tyeryar, Ashiwel S. Undie
-
Patent number: 7321065Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.Type: GrantFiled: April 16, 2004Date of Patent: January 22, 2008Assignees: The Regents of the University of California, Oregon Health & Science UniversityInventors: Thomas S. Scanlan, Matthew E. Hart, David K. Grandy, James R. Bunzow, Motonori Miyakawa, Edwin Saavedra Tan, Katherine L. Suchland
-
Publication number: 20080003275Abstract: The invention relates to methods and compositions for treating premature ejaculation in a male or prolonging intercourse comprising administering to the male an antidepressant via a route selected from the group consisting of mucosal administration (preferably nasal, buccal or rectal), administration to the lungs (preferably by inhalation), local administration to at least a part of the male genitalia (applied to the penis for example, in the form of a gel) and combinations thereof.Type: ApplicationFiled: July 9, 2004Publication date: January 3, 2008Applicant: Worldwide PE Patent Holdco Pty Ltd.Inventor: Jakov Vaisman
-
Patent number: 7273888Abstract: The present invention provides methods and compositions for modulating polyamine pathway activity as a means for ameliorating neurodegenarative disorders. In particular, for ameliorating the symptoms or onset of amyotrophic lateral sclerosis (ALS) by modulating the gene and protein products involved the polyamine pathway, such as by inhibiting the enzyme, ornithine decarboxylase (ODC), involved in the synthesis of the polyamine, putrescine. Compositions and methods are disclosed for inhibiting the polyamine pathway producing lower polyamine levels resulting in a beneficial effect on ALS. This can be accomplished by using modulating agents such as analogs, or polyamine analogs, and antiproliferative drugs. In particular, the ODC inhibitor difuoromethylornithine (DFMO) is disclosed as a useful pharmacological agent in the modulation and treatment of ALS. Screening assays for pharmacological agents that are capable of decreasing polyamine levels and/or reducing cell proliferation are also disclosed.Type: GrantFiled: November 1, 2002Date of Patent: September 25, 2007Assignee: ALS Therapy Development Foundation, Inc.Inventors: Tennore Ramesh, Sean Scott
-
Patent number: 7256204Abstract: A compound of the formula: wherein Ar is an aromatic ring assembly group which may be substituted or a fused aromatic group which may be substituted; X is (i) a bond, (ii) —S—, —SO— or —SO2—, (iii) C1-6 alkylene, C2-6 alkenylene or C2-6 alkynylene, etc.Type: GrantFiled: August 21, 2003Date of Patent: August 14, 2007Assignee: Takeda Pharmaceutical Company LimitedInventors: Kaneyoshi Kato, Jun Terauchi, Hiroaki Fukumoto, Mitsuru Kakihana
-
Patent number: 7244769Abstract: Impairments in memory consolidation are treated with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound. The method can include determining memory consolidation before, during and/or after administering the amphetamine compound.Type: GrantFiled: December 15, 2005Date of Patent: July 17, 2007Assignee: Cognition Pharmaceuticals, LLCInventors: Mel H. Epstein, Kjesten A. Wiig
-
Patent number: 7226951Abstract: Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.Type: GrantFiled: December 16, 2004Date of Patent: June 5, 2007Assignee: Allergan, Inc.Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Yin Tsang, Ling Li, Janet A. Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Vidyasagar Vuligonda, Roshantha A. Chandraratna
-
Patent number: 7223748Abstract: The invention provides a formulation to be administered as a dry powder for inhalation suitable for efficacious delivery of active ingredients into the low respiratory tract of patients suffering from a pulmonary disease such as asthma. In particular, the invention provides a formulation to be administered as dry powder for inhalation freely flowable, which can be produced in a simple way, is physically and chemically stable and capable of delivering both accurate doses and high fine particle fraction of low strength active ingredients by using a high- or medium resistance device.Type: GrantFiled: March 8, 2005Date of Patent: May 29, 2007Assignee: Chiesi Farmaceutici S.p.A.Inventors: John Nicholas Staniforth, David Alexander Vodden Morton, Rajbir Gill, Gaetano Brambilla, Rossella Musa, Lorenzo Ferrarini
-
Patent number: 7179926Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts and solvates, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.Type: GrantFiled: July 25, 2005Date of Patent: February 20, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Yazhong Huang, Shuanghua Hu, Andrew P. Degnan
-
Patent number: 7176243Abstract: This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of CaR receptor expressing cells of hematopoietic, neural, epithelial, endothelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. Specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. The invention also relates to methods for manipulating hematopoeitic progenitor cells and related products.Type: GrantFiled: November 1, 2001Date of Patent: February 13, 2007Assignees: The General Hospital Corporation, The Brigham and Women's Hospital, Inc.Inventors: Mark C. Poznansky, David T. Scadden, Ivona T. Olszak, Edward M. Brown
-
Patent number: 7157488Abstract: The present invention provides compounds of formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are antagonists of the 5-HT6 receptor. The present invention further provides a method of treating disorders associated with 5-HT6 receptors, including schizophrenia, anxiety, Alzheimer's disease, and cognitive disorders selected from the group consisting of age-related cognitive decline, mild cognitive impairment, and dementia, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.Type: GrantFiled: March 15, 2002Date of Patent: January 2, 2007Assignee: Eli Lilly and CompanyInventors: Zhaogen Chen, Michael Philip Cohen, Matthew Joseph Fisher, Bruno Giethlen, James Ronald Gillig, Jefferson Ray McCowan, Shawn Christopher Miller, John Mehnert Schaus
-
Patent number: 7148233Abstract: Methods for treating cardiovascular and related diseases such as hypertrophy are described. The methods are directed to concurrently administering a compound such as pyridoxal-5?-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with a therapeutic cardiovascular compound.Type: GrantFiled: August 12, 2003Date of Patent: December 12, 2006Assignee: Merrill Lynch Capital Canada Inc.Inventors: Rajat Sethi, Wasimul Haque
-
Patent number: 7147864Abstract: The present invention is directed to methods that can be used in the treatment of wounds, burns, and photodamaged skin. Methods can be used for both humans and animals and involve the administration of compositions containing selegiline and/or desmethylselegiline.Type: GrantFiled: March 23, 2004Date of Patent: December 12, 2006Assignee: Somerset Pharmaceuticals, Inc.Inventor: Mark G. Resnick
-
Patent number: 7144892Abstract: Methods for treating cardiovascular and related diseases such as myocardial infarction are described. The methods are directed to concurrently administering a compound such as pyridoxal-5?-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with a therapeutic cardiovascular compound.Type: GrantFiled: August 12, 2003Date of Patent: December 5, 2006Assignee: Merrill Lynch Capital Canada Inc.Inventors: Rajat Sethi, Wasimul Haque
-
Patent number: 7132430Abstract: Methods for treating cardiovascular and related diseases such as arrhythmia are described. The methods are directed to concurrently administering a compound such as pyridoxal-5?-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with a therapeutic cardiovascular compound.Type: GrantFiled: August 12, 2003Date of Patent: November 7, 2006Assignee: Medicure International Inc.Inventors: Rajat Sethi, Wasimul Haque
-
Patent number: 7125889Abstract: Methods for treating cardiovascular and related diseases such as blood clots are described. The methods are directed to concurrently administering a compound such as pyridoxal-5?-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with a therapeutic cardiovascular compound.Type: GrantFiled: August 12, 2003Date of Patent: October 24, 2006Assignee: Medicure International Inc.Inventors: Rajat Sethi, Wasimul Haque
-
Patent number: 7053122Abstract: The compounds of formula (I) are useful in the treatment of faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, neuropathic pain, neuropathological disorders and sleep disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.Type: GrantFiled: August 7, 2003Date of Patent: May 30, 2006Assignee: Pfizer IncInventors: Graham Nigel Maw, David James Rawson, Lisa Rosemary Thompson
-
Patent number: 7052833Abstract: Disclosed is a region on human chromosome 1 that provides a genetic basis for absorptive hypercalciuria. The genes, proteins, and other biological materials provided are envisioned for use in diagnostic and therapeutic methods related to absorptive hypercalciuria and osteoporosis with hypercalciuria.Type: GrantFiled: June 23, 1999Date of Patent: May 30, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Berenice Y. Reed-Gitomer, Charles Y. C. Pak
-
Patent number: 7026343Abstract: The c-Myc oncoprotein, a helix-loop-helix-leucine zipper (HLH-ZIP) transcription factor, is frequently deregulated in human cancers. All known functions of c-Myc, including those pertaining to transformation, require that it heterodimerize with another HLH-ZIP protein, Max. Using a high throughput yeast-based assay, we identified seven low molecular weight substances that inhibit c-Myc-Max association. Each compound also prevented this interaction in vitro and inhibited the growth of c-Myc-expressing fibroblasts, although not of fibroblasts lacking c-Myc. Finally, short-term exposure of c-Myc over expressing fibroblasts to several of the compounds markedly reduced their in vivo tumorigenicity. These studies suggest that yeast-based assays can be used to identify inhibitors of protein-protein interactions and that these frequently function in mammalian cells. The signature specificities of each of the c-Myc-Max compounds identified here further suggest synergistic in vivo function.Type: GrantFiled: June 12, 2003Date of Patent: April 11, 2006Assignee: University of Pittsburgh - of the Commonwealth System of Higher EducationInventors: Edward V. Prochownik, Christine Giap, John S. Lazo, Xiaoying Yin
-
Patent number: 7022882Abstract: Neuroprotectant agents are provided which do not contain peptides and axe protected from the degradation that limits the use of peptide-based drugs in systemic circulation. With great selectivity for NMDA receptors, the agents exert an open channel block on NMDA receptors, and protect neuronal cells containing such receptors from excitatoxic cell death.Type: GrantFiled: October 5, 2001Date of Patent: April 4, 2006Assignee: The Regents of the University of CaliforniaInventors: Kwok-Keung Tai, Sylvie E. Blondelle, Richard A. Houghten, Mauricio Montal
-
Patent number: 7001925Abstract: Polyamine compounds, method of synthesis and method of use for anti-cancer purposes, and for enhancing the activity of existing anti-cancer drugs are provided. This disclosure has identified certain polyamine motifs that can be attached to toxic agents to facilitate their access to cancer cells as well as polyamine compounds of surprising cytotoxicity and selectivity in killing cancer cells. It includes an illustrative conjugate system with examples of a triamine or a tetraamine appended to a cytotoxic agent. There are five method schemes illustrative of the synthesis of the compounds of the invention. Included is a general strategy to enhance cell uptake by attaching a polyamine vectoring system with an example of a triamine vector attached to an existing anti-cancer drug to improve its chemotherapeutic potency. There is an illustration of using the triamine vector to improve the selectivity of an anthracenylmethyl amine cytotoxic agent (e.g.Type: GrantFiled: September 19, 2003Date of Patent: February 21, 2006Assignee: University of Central Florida Research Foundation, Inc.Inventor: Otto Phanstiel
-
Patent number: 6979750Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.Type: GrantFiled: April 18, 2003Date of Patent: December 27, 2005Assignees: The Regents of the University of California, Oregon Health & Science UniversityInventors: Thomas S. Scanlan, Matthew E. Hart, David K. Grandy, James R. Bunzow
-
Patent number: 6974568Abstract: The invention discloses the existence of cannabinoid receptors in the airways, which are functionally linked to inhibition of cough. Locally acting cannabinoid agents can be administered to the airways of a subject to ameliorate cough, without causing the psychoactive effects characteristic of systemically administered cannabinoids. In addition, locally or systemically administered cannabinoid inactivation inhibitors can also be used to ameliorate cough. The present invention also defines conditions under which cannabinoid agents can be administered to produce anti-tussive effects devoid of bronchial constriction.Type: GrantFiled: May 23, 2001Date of Patent: December 13, 2005Assignee: The Regents of the University of CaliforniaInventor: Daniele Piomelli
-
Patent number: RE39593Abstract: 1-phenyl-3-dimethylaminopropane compounds corresponding to the formula I a method of preparing them, and the use of these substances as analgesic active ingredients in pharmaceutical compositions.Type: GrantFiled: June 17, 2003Date of Patent: April 24, 2007Assignee: Gruenenthal GmbHInventors: Helmut Buschmann, Wolfgang Strassburger, Elmar Friderichs